Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value (TSHA)

Historical Holders from Q3 2020 to Q3 2025

Symbol
TSHA on Nasdaq
Type / Class
Equity / Common Stock, $0.00001 par value
Shares outstanding
274,772,727
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
264,427,699
Holdings value
$864,676,435
% of all portfolios
0.01%
Number of holders
150
Number of buys
86
Number of sells
-55
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value (TSHA)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 9.9% 0% $90,456,313 +$7,574,932 27,662,481 +9.1% RA Capital Management, L.P. 30 Sep 2025
Manning Paul B 9.8% $59,394,578 25,601,111 Paul B Manning 30 May 2025
RTW INVESTMENTS, LP 9.9% -0.9% $66,483,878 +$11,906,347 25,183,287 +22% RTW Investments, LP 30 Jun 2025
MORGAN STANLEY 6.7% -21% $44,506,820 -$2,034,437 16,858,644 -4.4% Morgan Stanley 30 Jun 2025
FMR LLC 6.2% -22% $41,257,450 -$1,947,903 15,627,821 -4.5% FMR LLC 30 Jun 2025
BlackRock, Inc. 5.2% $30,389,444 13,153,326 BlackRock, Inc. 30 Jun 2025
GOLDMAN SACHS GROUP INC 5.1% $33,274,806 12,748,968 THE GOLDMAN SACHS GROUP, INC. 26 Jun 2025
Octagon Capital Advisors LP 3.3% -36% $29,650,725 -$4,520,775 9,067,500 -13% Octagon Capital Advisors LP 30 Sep 2025

Institutional Holders of Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value (TSHA)

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q3 264,427,699 $864,676,435 +$29,349,050 $3.27 150
2025 Q2 257,684,976 $595,324,582 +$211,768,578 $2.31 147
2025 Q1 166,761,354 $231,855,383 -$5,171,826 $1.39 124
2024 Q4 167,381,791 $289,604,775 +$18,983,312 $1.73 126
2024 Q3 156,893,147 $315,365,141 -$17,620,277 $2.01 114
2024 Q2 158,086,076 $354,139,573 +$33,881,138 $2.24 102
2024 Q1 140,148,555 $402,080,424 +$33,453,660 $2.87 106
2023 Q4 130,129,882 $230,288,972 -$12,329,934 $1.77 85
2023 Q3 129,862,060 $410,364,849 +$376,246,041 $3.16 59
2023 Q2 13,698,356 $9,051,371 -$2,014,707 $0.661 37
2023 Q1 16,687,605 $13,286,354 -$3,025,814 $0.7976 42
2022 Q4 19,375,255 $43,785,515 +$12,385,904 $2.26 51
2022 Q3 13,927,007 $27,020,000 -$1,811,564 $1.93 48
2022 Q2 14,700,530 $54,695,000 -$11,594,670 $3.72 55
2022 Q1 17,015,055 $110,894,239 -$16,224,000 $6.52 70
2021 Q4 18,503,286 $215,562,592 -$15,412,583 $11.65 64
2021 Q3 19,436,846 $361,910,267 +$4,396,852 $18.62 48
2021 Q2 18,320,557 $388,394,891 +$15,022,269 $21.2 48
2021 Q1 17,661,042 $358,518,075 -$11,587,017 $20.3 46
2020 Q4 17,998,551 $475,216,635 +$32,037,839 $26.54 51
2020 Q3 16,580,732 $366,712,000 +$366,712,000 $22.4 46